{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078322","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.910561+00:00","generated_at":"2026-05-31T23:08:12.528345+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Century Therapeutics updates pipeline; CNTY-101 achieves 40% CRR at higher doses; SLE trial starts Q3 2024","bullets":["CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.","CNTY-101 shows favorable safety: no GvHD, low-grade CRS/ICANS, manageable outpatient administration.","Phase 1 CALiPSO-1 trial for SLE (systemic lupus erythematosus) initiated early Q3 2024; initial data expected by YE 2024.","Cash of $249.9M at 1Q24 end provides runway into 2026.","Pursuing additional autoimmune regulatory submissions for CNTY-101 in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078322","json":"https://secwatch.observer/filing/0001104659-24-078322.json","markdown":"https://secwatch.observer/filing/0001104659-24-078322.md","text":"https://secwatch.observer/filing/0001104659-24-078322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/0001104659-24-078322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/tm2418927d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:08:12.528345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}